株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ナノメディシン市場:モダリティ、用途、適応別 - 世界の機会分析および業界予測

Nanomedicine Market by Modality (Treatments and Diagnostics), Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), and Indication - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 563339
出版日 ページ情報 英文 190 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.05円で換算しております。
Back to Top
ナノメディシン市場:モダリティ、用途、適応別 - 世界の機会分析および業界予測 Nanomedicine Market by Modality (Treatments and Diagnostics), Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), and Indication - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年08月01日 ページ情報: 英文 190 Pages
概要

当レポートでは、世界のナノメディシン市場について調査し、市場のモダリティ別、用途別、適応別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • ポーターズファイブフォース分析
  • 法規制と償還シナリオ
  • 市場シェア分析
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会

第4章 用途別市場

  • 概要
  • ワクチン
  • 再生医療
  • 画像診断
  • ドラッグデリバリー
  • インプラント
  • その他

第5章 適応別市場

  • 概要
  • 腫瘍疾患
  • 感染症
  • 心血管疾患
  • 整形外科疾患
  • 神経疾患
  • 泌尿器疾患
  • 眼科疾患
  • 免疫疾患
  • その他

第6章 モダリティ別市場

  • 概要
  • 治療
  • 診断

第7章 地域別市場

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ

第8章 企業プロファイル

目次
Product Code: LI 172021

Nanomedicine is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. These nanomedicines have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods. The global nanomedicine market accounted for $111,912 million in 2016, and is anticipated to reach $261,063 million by 2023, registering a CAGR of 12.6% from 2017 to 2023.

The global nanomedicine market is driven by emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, rise in government support and funding, and growth in need for safe and cost-effective therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. Based on indication, it is categoried into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopaedic disorders, immunological diseases, cardiovascular diseases, and others. On the basis of modality, it is bifurcated into treatments and diagnostics.

Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in the global market, owing to increase in presence of stronger players focussed on R&D activities and commercialization of nanomedicines in the region. In addition, this region leads in the number of nanotechnology patent applications resulting in higher demand in the market. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the rapid development of healthcare infrastructure and growth in health awareness among the middle-class population.

The key players operating in the global market have focused on expanding their presence in the nanomedicine sector. Moreover, new players moving into healthcare contribute by expanding expertise range, leveraging diversification, and augmenting scale by providing the necessary capital for the nanomedicine development.

KEY BENEFITS FOR STAKEHOLDERS:

  • The study provides an in-depth analysis of the global nanomedicine market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on product assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS:

By Application

  • Drug Delivery
  • Vaccines
  • Diagnostic Imaging
  • Regenerative Medicine
  • Implants
  • Others

By Modality

  • Diagnostics
  • Treatments

By Indication

  • Oncological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Orthopedic Disorders
  • Neurological Diseases
  • Urological Diseases
  • Ophthalmological Diseases
  • Immunological Diseases
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Argentina
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY PLAYERS PROFILED:

  • Abbott Laboratories
  • CombiMatrix Corporation
  • General electric Company
  • Sigma-Tau Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Mallinckrodt plc.
  • Merck & Company, Inc.
  • Nanosphere, Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • The other players in the value chain include (profiles not included in the report)
  • Celgene Corporation
  • UCB (Union Chimique Belge) S.A.
  • AMAG Pharmaceuticals
  • Nanospectra Biosciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Leadiant Biosciences, Inc.
  • Epeius Biotechnologies Corporation
  • Gilead
  • Cytimmune Sciences, Inc.
  • NanoCarrier
  • LTT BioPharma
  • Mebiopharm

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. REGULATION AND REIMBURSEMENT SCENARIO
    • 3.4.1. FDA
    • 3.4.2. Health Canada
    • 3.4.3. CE Mark
    • 3.4.4. Ministry of Health, Labor, and Welfare (MHLW)
  • 3.5. MARKET SHARE ANALYSIS, 2016
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Emerging innovative technologies for drug delivery
      • 3.6.1.2. Increase adoption of nanomedicine across varied applications
      • 3.6.1.3. Rising government support and funding
      • 3.6.1.4. Growing need of therapies that have fewer side effects and are cost effective
    • 3.6.2. Restraints
      • 3.6.2.1. Long approval process
      • 3.6.2.2. Risks associated with nanomedicine (environmental impacts)
    • 3.6.3. Opportunities
      • 3.6.3.1. Growth of healthcare facilities in emerging economies

CHAPTER 4 NANOMEDICINE MARKET, BY APPLICATION

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. VACCINES
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. REGENERATIVE MEDICINE
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. DIAGNOSTIC IMAGING
    • 4.4.1. Key market trends
    • 4.4.2. Growth factors and opportunities
    • 4.4.3. Market size and forecast
  • 4.5. DRUG DELIVERY
    • 4.5.1. Key market trends
    • 4.5.2. Growth factors and opportunities
    • 4.5.3. Market size and forecast
  • 4.6. IMPLANTS
    • 4.6.1. Key market trends
    • 4.6.2. Growth factors and opportunities
    • 4.6.3. Market size and forecast
  • 4.7. OTHERS
    • 4.7.1. Key market trends
    • 4.7.2. Growth factors and opportunities
    • 4.7.3. Market size and forecast

CHAPTER 5 NANOMEDICINE MARKET, BY INDICATION

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. ONCOLOGICAL DISEASES
    • 5.2.1. Market size and forecast
  • 5.3. INFECTIOUS DISEASES
    • 5.3.1. Market size and forecast
  • 5.4. CARDIOVASCULAR DISEASES
    • 5.4.1. Market size and forecast
  • 5.5. ORTHOPEDIC DISORDERS
    • 5.5.1. Market size and forecast
  • 5.6. NEUROLOGICAL DISORDERS
    • 5.6.1. Market size and forecast
  • 5.7. UROLOGICAL DISEASES
    • 5.7.1. Market size and forecast
  • 5.8. OPHTHALMOLOGICAL DISEASES
    • 5.8.1. Market size and forecast
  • 5.9. IMMUNOLOGICAL DISEASES
    • 5.9.1. Market size and forecast
  • 5.10. OTHERS
    • 5.10.1. Market size and forecast

CHAPTER 6 NANOMEDICINE MARKET, BY MODALITY

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. TREATMENTS
    • 6.2.1. Market size and forecast
  • 6.3. DIAGNOSTICS
    • 6.3.1. Market size and forecast

CHAPTER 7 NANOMEDICINE MARKET, BY REGION

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. NORTH AMERICA
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. Market size and forecast
      • 7.2.3.1. U.S. market size and forecast
      • 7.2.3.2. Mexico market size and forecast
      • 7.2.3.3. Canada market size and forecast
  • 7.3. EUROPE
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast
      • 7.3.3.1. Germany market size and forecast
      • 7.3.3.2. UK market size and forecast
      • 7.3.3.3. France market size and forecast
      • 7.3.3.4. Italy market size and forecast
      • 7.3.3.5. Spain market size and forecast
      • 7.3.3.6. Rest of Europe market size and forecast
  • 7.4. ASIA-PACIFIC
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast
      • 7.4.3.1. India market size and forecast
      • 7.4.3.2. China market size and forecast
      • 7.4.3.3. Japan market size and forecast
      • 7.4.3.4. Australia market size and forecast
      • 7.4.3.5. Rest of Asia-Pacific market size and forecast
  • 7.5. LAMEA
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. Market size and forecast
      • 7.5.3.1. Brazil market size and forecast
      • 7.5.3.2. South Africa market size and forecast
      • 7.5.3.3. South Arabia market size and forecast
      • 7.5.3.4. Argentina market size and forecast
      • 7.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Business performance
    • 8.1.5. Key strategic moves and developments
  • 8.2. COMBIMATRIX CORPORATION
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Business performance
    • 8.2.5. Key strategic moves and developments
  • 8.3. GENERAL ELECTRIC COMPANY
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
    • 8.3.5. Key strategic moves and developments
  • 8.4. SIGMA-TAU PHARMACEUTICALS, INC.
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Key strategic moves and developments
  • 8.5. JOHNSON & JOHNSON PRIVATE LIMITED
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Business performance
    • 8.5.5. Key strategic moves and developments
  • 8.6. MALLINCKRODT PLC
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
    • 8.6.5. Key strategic moves and developments
  • 8.7. MERCK & COMPANY, INC.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Business performance
    • 8.7.5. Key strategic moves and developments
  • 8.8. LUMINEX CORPORATION
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Business performance
    • 8.8.5. Key strategic moves and developments
  • 8.9. PFIZER, INC.
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Business performance
    • 8.9.5. Key strategic moves and developments
  • 8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Business performance
    • 8.10.5. Key strategic moves and developments
Back to Top